Quick Answer
Edesa Biotech, Inc. reported Operating Income Loss of -$7.91 million for the year ending 2025.
- Edesa Biotech, Inc. showed a decrease of -12.8% in Operating Income Loss from 2024 to 2025.
- This data is from Edesa Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on December 12, 2025.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2015: -$1.31 million | Q1 2016: -$1.10 million | Q2 2016: -$1.19 million | Q4 2016: -$1.41 million | Q1 2017: -$1.15 million | Q2 2017: -$1.29 million | Q4 2017: -$1.39 million | Q1 2018: -$1.34 million | Q2 2018: -$422.0 thousand | Q4 2018: -$405.7 thousand | Q1 2019: -$540.8 thousand | Q2 2019: -$1.32 million | Q4 2019: -$1.11 million | Q1 2020: -$1.52 million | Q2 2020: -$1.77 million | Q4 2020: -$2.61 million | Q1 2021: -$9.51 million | Q2 2021: -$6.07 million | Q4 2021: -$5.16 million | Q1 2022: -$4.58 million | Q2 2022: -$5.80 million | Q4 2022: -$2.38 million | Q1 2023: -$2.41 million | Q2 2023: -$2.06 million | Q4 2023: -$1.86 million | Q1 2024: -$2.22 million | Q2 2024: -$1.93 million | Q4 2024: -$1.90 million | Q1 2025: -$1.64 million | Q2 2025: -$1.90 million | Q4 2025: -$2.34 million.
- Over the full 12 years of available data (2014 to 2025), Edesa Biotech, Inc.'s Operating Income Loss has declined by 38.3%.
- Historical annual values: Fiscal year 2025: -$7.91 million | Fiscal year 2024: -$7.01 million | Fiscal year 2023: -$9.22 million | Fiscal year 2022: -$18.37 million | Fiscal year 2021: -$23.68 million | Fiscal year 2020: -$6.40 million | Fiscal year 2018: -$5.08 million | Fiscal year 2017: -$5.22 million | Fiscal year 2016: -$4.91 million | Fiscal year 2015: -$4.34 million | Fiscal year 2014: -$452.3 thousand | Fiscal year 2014: -$5.72 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: